PYC Therapeutics’ drug to treat a blinding disease is heading to human trials after agreement between the company and the US FDA. Following pre-IND meeting with the FDA, PYC now anticipates ...
Following pre-IND meeting with the FDA, PYC now anticipates progressing its drug candidate for ADOA (autosomal dominant optic atrophy) to human trials in the first half of calendar year 2024.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results